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Increase in heme oxygenase-1 levels ameliorates renovascular
hypertension.
Background. The heme oxygenase system (HO-1 and HO-2)
catalyzes the conversion of heme to free iron, carbon monox-
ide (CO), a vasodepressor, and biliverdin, which is further con-
verted to bilirubin, an antioxidant. HO-1 induction has been
shown to suppress arachidonic acid metabolism by cytochrome
P450 (CYP450) monooxygenases and cyclooxygenases (COX),
and to decrease blood pressure in spontaneously hypertensive
rats (SHR). The Goldblatt 2K1C model is a model of reno-
vascular hypertension in which there is increased expression of
COX-2 in the macula densa and increased renin release from
the juxtaglomerular apparatus of the clipped kidney. We exam-
ined whether HO-1 overexpression, as a prophylactic approach,
would attenuate renovascular hypertension and evaluated po-
tential mechanisms that may account for its effect.
Methods. 2K1C rats were treated with cobalt protoporphyrin
(CoPP) or tin mesoporphyrin (SnMP) one day before surgery
and weekly for three weeks thereafter. We measured systolic
blood pressure, HO activity, HO-1, HO-2, COX-1 and COX-
2 protein expression, heme content, and nitrotyrosine levels
as indices of oxidative stress. Urinary prostaglandin excretion
(PGE2), plasma renin activity (PRA), and plasma aldosterone
levels were also measured.
Results. CoPP administration induced renal HO-1 expression
by 20-fold and HO activity by 6-fold. This was associated with
a reduction in heme content, nitrotyrosine levels, COX-2 ex-
pression and urinary PGE2 excretion, and attenuation of the
development of hypertension in the 2K1C rats. There was no
decrease in plasma renin activity; however, plasma aldosterone
levels were significantly lower. In the 2K1C SnMP-treated rats,
blood pressure was significantly higher than that of untreated
2K1C rats throughout the study, and the difference in the size
of the smaller left clipped kidney compared to the nonclipped
right kidney was significantly increased.
Conclusion. These findings define an action of prolonged
HO-1 induction to interrupt and counteract the influence of
the renin-angiotensin-aldosterone system (RAAS) to increase
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in blood pressure in the 2K1C model of renovascular hyperten-
sion. Multiple mechanisms include a decrease in oxidative stress
as indicated by the decrease in cellular heme and nitrotyrosine
levels, an anti-inflammatory action as evidenced by a decrease in
COX-2 and PGE2, interference with the action of angiontensin
II (Ang II) as evidenced by an increase in PRA in the face of a
decrease in PGE2 and aldosterone, as well as the inhibition of
aldosterone synthesis.
Heme functions as the prosthetic moiety for a num-
ber of heme-containing proteins with activities that are
critical to vascular and renal function. These include
soluble guanylate cyclase, nitric oxide synthase (NOS),
and enzymes of the eicosanoid biosynthetic pathways,
including cytochrome P450 (CYP450) monooxygenases,
thromboxane and prostacyclin synthases, and the heme-
dependent cyclooxygenases (COX) [1–5]. Heme oxyge-
nase (HO), as the key enzyme in heme degradation, not
only controls cellular levels of heme available for the syn-
thesis of heme proteins, but is also responsible for gener-
ating bilirubin, an antioxidant, and the vasodepressor gas,
carbon monoxide (CO), from heme. The CO can bind to
the heme moiety of heme proteins, causing either enzyme
activation or inhibition [3].
To date, two HO isoforms (HO-1 and HO-2), the prod-
ucts of two distinct genes, have been shown to be impor-
tant in the catabolism of heme in mammals. HO-2, which
is constitutively expressed, is localized primarily in the
brain, testis, and the vascular endothelium [3, 6, 7]. HO-1
is an inducible isoform with widespread tissue distribu-
tion, including liver, kidney, and lung [3]. In earlier stud-
ies, we and others demonstrated that overexpression of
the HO-1 gene in human, rabbit, and rat endothelial cells
not only renders the cells resistant to agents that elicit
oxidative stress [3, 8–10], but also enhances cell growth
[9, 11, 12] and angiogenesis [13]. A decrease in HO-1
gene expression promotes elevation of cellular heme, a
pro-oxidant associated with increased free radicals and
cellular lipid peroxidation. In contrast, robust HO-1 over-
expression has been shown to increase the antioxidant
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properties of the cells, which results in attenuation of ox-
idative injury and formation of adhesion molecules [14].
Numerous studies have implicated the heme-HO sys-
tem in the regulation of blood pressure. These studies
attribute the blood pressure lowering effect of HO-1
induction to various mechanisms, including decreased
production of vasoconstrictor eicosanoids and increased
production of CO [2, 15, 16]. CO has been shown to
function as a vasodilator [17–21], a stimulator of solu-
ble guanylate cyclase [22], an endogenous modulator of
the cGMP signaling system [4], an activator of calcium-
activated potassium channels (KCa) in vascular smooth
muscle [23], and an inhibitor of endothelin-1 mediated
vasoconstriction [18, 24, 25]. Recent reports have impli-
cated HO in the regulation of renal salt excretion. CO
generated by HO-dependent heme catabolism has been
shown to stimulate the apical 70-pS K-channel [26]. In-
hibition of HO has been shown to decrease sodium and
fluid reabsorption in the thick ascending limb of the loop
of Henle in the rat [27]. Furthermore, exogenous heme
administration has been shown to induce HO-dependent
natriuresis and diuresis, which were blocked by pretreat-
ment with SnMP [28]. These reports further underscore
the potential importance of HO in the regulation of kid-
ney function.
The Goldblatt 2 kidney 1 clip (2K1C) model is a model
for renovascular hypertension [29] characterized by the
elevation of oxidants due to activation of the renin-
angiotensin-aldosterone system (RAAS). The clipped
kidney is responsible for renin release and ultimately for
the increase in blood pressure, whereas the nonclipped
kidney exhibits subnormal renin content [30]; however,
elevated angiotensin II (Ang II) levels cause the non-
clipped kidney to exhibit increased renal vascular resis-
tance, leading to impairment of autoregulation [31] and
tubuloglomerular feedback. Several studies have shown
a relationship between the increase in renin release and
an increase in COX-2 expression in the cortical thick as-
cending loop of Henle and in the region of the macula
densa [32–34]. Aldosterone can stimulate COX-2 in the
kidney and heart, and has been reported to induce vas-
cular inflammatory phenotypes [35–37].
The objective of this study was to examine the conse-
quences of HO-1 induction and HO inhibition on the re-
nal heme-HO system, oxidant levels, and blood pressure
in the 2K1C renovascular hypertension model. We mea-
sured systolic blood pressure, HO activity, HO-1, HO-2,
COX-1 and COX-2 protein expression, heme content,
and nitrotyrosine levels as indices of oxidative stress.
Urinary prostaglandin (PGE2) excretion, plasma renin
activity (PRA), and plasma aldosterone levels were also
measured. Our results demonstrated that basal levels of
the constitutively expressed HO-2 were not increased,
but heme content and nitrotyrosine levels were increased
in the 2K1C model compared to sham animals. Ad-
ministration of cobalt protoporphyrin (CoPP), a potent
inducer of HO-1 protein and activity, attenuated the de-
velopment of hypertension, possibly by decreasing cel-
lular heme and oxidant levels and/or by increasing the
production of CO and bilirubin. Inhibition of HO ac-
tivity by tin mesoporphyrin (SnMP) magnified oxidative
stress, thus, substantiating a significant role for HO-1 as
part of the cellular defense system against oxidant dam-
age and maintaining renal hemodynamic function in the
2K1C model. These findings also suggest that there is a
significant link between the heme-HO system and the
levels of heme-dependent oxidants in the development
of hypertension in 2K1C rats.
METHODS
Animal treatment
Male Sprague-Dawley (SD) rats (200–250 g body
weight; Charles River Lab, Wilmington, MA, USA) were
housed 4 to 5 days before the beginning of the study. Tail
blood pressure was measured without anesthesia, using
the tail cuff method, at least twice before the surgery.
Animals were anesthetized with pentobarbital, and a U-
shaped silver clip with an internal gap of 0.25 mm was
placed around the left renal artery. Four groups of rats
were studied: sham operated animals, 2K1C control rats,
2K1C rats pretreated with CoPP (5 mg/100 g body wt)
24 hours before surgery, and 2K1C rats pretreated with
SnMP (5 mg/100 g body wt) 24 hours before surgery. Each
group contained 18 animals; a total of 72 rats were used.
Weekly injections of CoPP (5 mg/100 g body wt) were
administered subcutaneously to the CoPP group. SnMP
(5 mg/100 g body wt) was administered intraperitoneally
three times a week to the SnMP group for three weeks.
Sham and control 2K1C rats were injected with saline.
There was no mortality in the rats with the use of vari-
ous drugs including CoPP and SnMP. Blood pressure was
measured twice a week for three weeks. Blood samples
were collected in K3EDTA tubes, centrifuged at 2500g
for 10 minutes at 4◦C to separate the plasma, which was
stored at −20◦C. On the last day before sacrifice, rats were
housed in metabolic cages for urine collection. Rats were
sacrificed on day 21 after the surgery.
Tissue preparation
Kidneys were immediately excised, weighed and
frozen at −80◦C until use. Tissues were homogenized
(4 mL/g wet weight) in buffer, pH 7.4, containing
0.25 mol/L sucrose. The homogenate was centrifuged at
10,000g for 10 minutes at 4◦C. The cell-free homogenate
(10,000g supernatant) was used for Western blot analyses
or activity assays. Protein concentration was determined
according to the method of Bradford and Marshal (Bio-
Rad, Hercules, CA, USA).
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Western blot analysis
Western blot analysis of HO-1, HO-2, COX-1, and
COX-2 proteins was performed as previously described
[2]. Cell-free homogenates (10,000g supernatant) of kid-
ney preparations (20 lg protein) were separated by
sodium dodecyl sulfate (SDS)/polyacrylamide gel elec-
trophoresis and transferred to a nitrocellulose membrane
using a semidry transfer apparatus (Bio-Rad). The mem-
branes were incubated with 5% milk in 10 mmol/L Tris-
HCl, pH 7.4, 150 mmol/L NaCl, 0.05% Tween 20 (TBST)
buffer at 4◦C overnight. After washing with TBST, the
membranes were incubated for 1 hour with rabbit anti-
rat HO-1 or HO-2 polyclonal antibodies (1:1000; Stress-
gen Biotechnologies Corp., Victoria, BC, Canada) or
rabbit antimouse COX-1 or COX-2 polyclonal antibod-
ies (1:250; Cayman Chemical, Ann Arbor, MI, USA).
The filters were then washed and subsequently probed
with horseradish peroxidase–conjugated donkey antirab-
bit IgG for HO-1, HO-2, COX-1, or COX-2. Chemilumi-
nescence detection was performed with the Amersham
ECL detection kit (Amersham, Piscataway, NJ, USA) ac-
cording to the manufacturer’s instructions.
Measurement of HO activity and heme content
Tissue segments were homogenized (4 mL/g wet
weight) in homogenization buffer (pH 7.4), containing
0.25 mol/L sucrose. The homogenates were centrifuged
at 10,000g for 10 minutes at 4◦C. The supernatant was
then used for measuring HO activity. HO activity was
assayed [2] in which bilirubin, the end product of heme
degradation, was extracted with chloroform and its con-
centration was determined spectrophotometrically (Dual
UV/VIS Beam Spectrophotometer Lambda 25; Perkin-
Elmer, Norwalk, CT, USA) using the difference in ab-
sorbance at wavelength from k 460 to k 530 nm with an
absorption coefficient of 40 mmol/L−1 and cm−1.
Heme content was determined by the pyridine
hemochromogen method [2]. The absorbance differ-
ence between k 557 and k 530 nm was used to calcu-
late the heme content using an extinction coefficient of
20.7 mmol/L−1 and cm−1.
Measurement of nitrotyrosine
Nitrotyrosine is a marker for peroxynitrite-mediated
oxidative stress and has been regarded as a sensitive
marker of oxidative damage. Nitrotyrosine residues were
assessed by Western blot analysis with a rabbit anti-
nitrotyrosine antibody (Cayman Chemical).
Urinary PGE2 excretion
Urinary excretion rate for PGE2 was determined using
an ELISA (EIA) kit (Cayman Chemical).
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Fig. 1. Effect of treatment with CoPP (5 mg/100 g body wt/week) or
SnMP (three doses of 5 mg/100 g body wt/week) for three weeks on
systolic blood pressure in 2K1C rats. Results are expressed as mean ±
SE for each group. ∗P < 0.05 vs. sham, #P < 0.05 vs. 2K1C.
Plasma renin activity and aldosterone levels
PRA was determined using commercially available
radioimmunoassay (RIA) kits (Perkin Elmer Life Sci-
ences, Boston, Massachusetts, USA; or DiaSorin, Still-
water, MN, USA). Briefly, frozen plasma samples were
thawed on ice, diluted with maleate buffer (pH 6.0), and
incubated with exogenous renin substrate (plasma from
48-hour nephrectomized rats) in the presence of dimer-
caprol and 8-hydroxyquinoline for 1 hour at 37◦C. RIA
was performed to measure Ang I produced in the incuba-
tion medium. Plasma aldosterone levels were determined
with a commercially available RIA kit (Diagnostic Prod-
ucts Corp., Los Angeles, CA, USA).
Statistical analysis
Results are presented as mean ± standard error (SE)
for the number (N) of replicate determinations. Statistical
significance between the experimental groups was deter-
mined by using one-way analysis of variance (ANOVA)
followed by the Fisher least significant difference (LSD)
multiple-comparison test; P < 0.05 was considered sig-
nificant. Blood pressure measurements were analyzed by
using repeated measures ANOVA followed by the Fisher
LSD multiple-comparison test; P < 0.05 was considered
significant.
RESULTS
Effect of HO expression on development of hypertension
In the sham rats, blood pressure did not change
throughout the study. However, in the 2K1C rats, blood
pressure was significantly increased by day five and re-
mained significantly elevated. Twenty days post clipping,
systolic blood pressure in the untreated 2K1C rats was sig-
nificantly higher than that of the sham rats (179 ± 4 mm
Hg, N = 14 vs. 131 ± 1 mm Hg, P < 0.05) (Fig. 1). Relative
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Fig. 2. (A) Western blot and densitometry
analysis showing the effect of treatment with
CoPP (5 mg/100 g body wt/week) for three
weeks on HO-1 and HO-2 protein expression
in the clipped kidney of 2K1C rats (N = 6).
(B) Western blot and densitometry analysis
showing the effect of treatment with SnMP
(three doses of 5 mg/100 g body wt/week) for
three weeks on HO-1 and HO-2 protein ex-
pression in the clipped kidney of 2K1C rats
(N = 3). (C) The effect of treatment with
CoPP (5 mg/100 g body wt/week) or SnMP
(5 mg/100 g body wt/week) for three weeks
on HO activity in the clipped kidney of 2K1C
rats. Results are expressed as mean ±SE. ∗P <
0.05 vs. sham, #P < 0.05 vs. 2K1C.
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Fig. 3. Effect of treatment with CoPP (5 mg/100 g body wt/week) or
SnMP (three doses of 5 mg/100 g body wt/week) for three weeks on
heme content in the clipped kidney of 2K1C rats. Results are expressed
mean ± SE. ∗P < 0.05 vs. sham, #P < 0.05 vs. 2K1C.
to sham rats, treatment with CoPP, a potent inducer of
HO-1 protein and activity, markedly attenuated the de-
velopment of hypertension. Twenty days after clipping,
systolic blood pressure in the CoPP-treated 2K1C rats
was significantly lower than that of the untreated 2K1C
rats (134 ± 4 mm Hg vs. 179 ± 4 mm Hg, P < 0.05), and was
not different than that of the sham rats (134 ± 4 mm Hg
vs. 131 ± 1 mm Hg) (Fig. 1). To examine the effect of HO
inhibition on the development of hypertension, we used
the potent HO activity inhibitor, SnMP. Twenty days post
clipping, systolic blood pressure in SnMP-treated 2K1C
rats was significantly higher than that of the untreated
2K1C rats (190.2 ± 15.3 mm Hg vs. 179.0 ± 3.5 mm Hg,
P < 0.05) (Fig. 1).
Effect of HO inducers and inhibitors on the levels
of HO-1 and HO-2
The increase in blood pressure in 2K1C rats was also
associated with an increase in clipped kidney HO-1 ex-
pression and HO activity. As seen in Figure 2A, HO-1
expression was significantly increased in clipped kidneys
from 2K1C rats compared to kidneys from sham rats;
however, Western blot analysis revealed no significant
difference in HO-2 protein expression (Fig. 2B). Plotting
the ratio of HO-1/actin to document the relative increase
in HO-1 showed that HO-1 protein was not significantly
increased in the 2K1C (sham vs. 2K1C). Renal HO activ-
ity was significantly higher in clipped kidneys from 2K1C
rats compared to sham rats (0.230 ± 0.016 nmol biliru-
bin/mg/hr vs. 0.182 ± 0.01 nmol bilirubin/mg/hr, N = 6,
P < 0.05) (Fig. 2C).
Treating 2K1C rats with CoPP increased HO-1 pro-
tein expression by 20-fold (Fig. 2A); in contrast, HO-
2 protein levels did not change (Fig. 2A). There was
also a 6-fold increase in HO activity in clipped kidneys
from CoPP-treated 2K1C rats versus untreated 2K1C rats
(1.261±0.135 nmol bilirubin/mg/hr vs. 0.330±0.016 nmol
bilirubin/mg/hr, N = 6, P < 0.05) (Fig. 2C). Untreated
2K1C rats have a minimally significant increase in HO-1,
whereas 2K1C-CoPP has a highly significant increase in
HO-1 protein. Relative to untreated 2K1C rats, a signifi-
cant increase in HO-1 protein expression was detected in
the SnMP-treated 2K1C rats (Fig. 2B); the similarity of
the SnMP structure to CoPP resulted in gene activation
of HO-1. Although SnMP, like CoPP, is an inducer of HO-
1 protein expression, it is also a potent inhibitor of HO
activity and is used clinically to control hyperbilirubine-
mia [38]. SnMP-treated 2K1C rats had significantly lower
renal HO activity (0.0268 ± 0.004 nmol bilirubin/mg/hr,
N = 5, P < 0.05) (Fig. 2C). CoPP and SnMP increased
HO-1 proteins in the unclipped kidney (data not shown).
Effect of heme-HO system on renal heme
Clipped kidney homogenate from 2K1C rats showed
significantly higher levels of heme than that from sham
rats (1.93 ± 0.23 nmol/mg protein vs. 1.31 ± 0.12 nmol/mg
protein, P < 0.05) (Fig. 3). Heme content was significantly
lower in CoPP-treated 2K1C rats compared to untreated
2K1C rats (1.10 ± 0.13 nmol/mg protein, N = 5 vs. 1.93 ±
0.23 nmol/mg protein, P < 0.05) (Fig. 3). Heme content in
the clipped kidney tissue homogenate of SnMP-treated
2K1C rats was not significantly different from that of un-
treated 2K1C rats (2.07 ± 0.20 nmol/mg protein vs. 1.93 ±
0.23 nmol/mg protein) (Fig. 3).
Effect of HO inducers and inhibitors
on nitrotyrosine levels
Because peroxynitrite has been shown to be increased
in renovascular hypertension [39, 40], we measured ni-
trotyrosine levels using Western blot analysis. Relative
to sham rats, clipped kidneys from 2K1C rats showed
significantly higher levels of nitrotyrosine (Fig. 4). The
increased HO activity and decreased heme content in
CoPP-treated 2K1C rats were associated with significant
decrease in the levels of nitrotyrosine immunoreactivity
in the clipped kidney (Fig. 4). Treating 2K1C rats with
SnMP significantly increased clipped kidney nitrotyro-
sine levels (Fig. 4). These results demonstrate that clipped
kidney tissue from 2K1C rats had a higher level of oxida-
tive stress, which was decreased with CoPP, but increased
with SnMP, indicating that induction of HO-1 activity pro-
vided protection against oxidative stress.
Effect of HO inducers and inhibitors on COX-1 and
COX-2 and urinary PGE2
Western blot analysis of clipped kidney homogenate
revealed significantly higher levels of COX-2 protein ex-
pression compared to sham kidneys (Fig. 5A). In contrast,
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Fig. 4. Western blot and densitometry analysis showing the effect of treatment with CoPP (5 mg/100 g body wt/week) for three weeks or SnMP
(three doses of 5 mg/100 g body wt/week) on nitrotyrosine (NT) levels in the clipped kidney. Results are expressed mean ± SE. ∗P < 0.05 vs. sham,
#P < 0.05 vs. 2K1C.
significant COX-1 levels were detected both in sham kid-
neys and in clipped kidneys from untreated 2K1C rats
(Fig. 5B). Three weeks after clipping, urinary PGE2 ex-
cretion was significantly higher in 2K1C rats versus sham
rats (83 ± 18 ng PGE2/24 hr vs. 47 ± 4 ng PGE2/24 hr, P <
0.05) (Fig. 5C). Compared to untreated 2K1C rats, treat-
ment with CoPP significantly decreased COX-2 levels in
the clipped kidney (Fig. 5A); in contrast, COX-1 protein
levels did not change (Fig. 5B). In the CoPP-treated 2K1C
rats, urinary PGE2 excretion was significantly lower than
that of untreated 2K1C (9±5 ng PGE2/24 hr vs. 83±18 ng
PGE2/24 hr, P < 0.05) (Fig. 5C). Clipped kidney COX-2
expression was not significantly higher in SnMP treated
2K1C than that of the untreated 2K1C rats, and COX-
1 protein levels did not change in clipped kidneys from
SnMP-treated 2K1C rats compared to untreated 2K1C
rats (Fig. 5). In addition, treatment with SnMP did not
significantly affect the levels of urinary PGE2 excretion
(Fig. 5C). Since COX-2 was decreased, but not COX-1,
this would suggest that the major portion of urinary PGE2
excretion in 2K1C rats is COX-2–derived.
Effect of heme-HO expression on plasma renin activity
PRA was significantly higher in 2K1C rats compared to
sham rats (147 ± 16 ng Ang I/mL/hr vs. 50 ± 11 ng Ang
I/mL/hr, P < 0.05) (Fig. 6). Although CoPP treatment
caused a significant decrease in blood pressure, there
was a significant increase in PRA compared to untreated
2K1C (Fig. 6). Treating 2K1C rats with SnMP did not
have a significant effect on PRA, although it was higher
compared to untreated 2K1C (268 ± 53 ng Ang I/mL/hr,
N = 4 vs. untreated 2K1C) (Fig. 6).
Effect of HO expression on plasma aldosterone levels
Plasma collected from 2K1C rats showed significantly
higher levels of aldosterone compared to sham rats (613±
72 pg/mL vs. 307 ± 49 pg/mL, P < 0.05) (Fig. 7). Although
CoPP increased PRA more than 2-fold higher than that in
the untreated 2K1C rats, plasma aldosterone levels were
significantly lower than that of the untreated 2K1C rats
(411 ± 59 pg/mL vs. 613 ± 72 pg/mL, P < 0.05) (Fig. 7).
Plasma aldosterone levels were significantly higher in rats
treated with SnMP than those of the sham rats (552 ±
12 pg/mL vs. 307 ± 49 pg/mL, P < 0.05), but were not sig-
nificantly different from the untreated 2K1C rats (Fig. 7).
Effect of HO expression on relative size of the kidney,
clipped (L) versus non-clipped (R)
As seen in Table 1 and as expected, the relative size of
the two kidneys (clipped/non-clipped) was significantly
decreased in the 2K1C rats. However, up-regulation of
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Fig. 5. (A) Western blot and densitometry analysis showing the effect of treatment with CoPP (5 mg/100 g body wt/week) (N = 11) or SnMP
(three doses of 5 mg/100 g body wt/week) (N = 3) for three weeks on COX-2 protein expression in the clipped kidney of 2K1C rats. (B) Western
blot and densitometry analysis showing the effect of treatment with CoPP (5 mg/100 g body wt/week) (N = 9) or SnMP (three doses of 5 mg/100 g
body wt/week) (N = 3) for three weeks on COX-1 protein expression in the clipped kidney of 2K1C rats. (C) The effect of treatment with CoPP
(5 mg/100 g body wt/week) or SnMP (three doses of 5 mg/100 g body wt/week) for three weeks on urinary PGE2 excretion in 2K1C rats. Results
are expressed mean ± SE. ∗P < 0.05 vs. sham, #P < 0.05 vs. 2K1C.
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in 2K1C rats. Results are expressed mean ± SE. ∗P < 0.05 vs. sham, #P <
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Fig. 7. Effect of treatment with CoPP (5 mg/100 g body wt/week) or
SnMP (three doses of 5 mg/100 g body wt/week) on plasma aldosterone
levels in 2K1C rats. Results are expressed mean ± SE. ∗P < 0.05 vs.
sham, #P < 0.05 vs. 2K1C.
HO-1 and HO activity by CoPP significantly improved
the clipped/non-clipped (L/R) kidney weight ratio, indi-
cating possible increased preservation of kidney tissue.
In contrast, inhibition of HO by SnMP magnified the ef-
fect of renal artery clipping on kidney size (P < 0.05)
and decreased the size of the clipped kidney compared
to untreated 2K1C. Figure 8 illustrates the effect of in-
hibition and induction of HO-1 using SnMP and CoPP,
respectively, on the size of the clipped kidney, demon-
strating the differential effect of HO-1 levels and HO
activity on renal cytoprotection. The increase in HO ac-
tivity by CoPP caused a 65% increase in clipped kidney
size compared to the effect of inhibition of HO activity
by SnMP (P < 0.0001).
DISCUSSION
In this report, we have demonstrated that induction
of HO-1 lowers blood pressure in the 2K1C model of
renovascular hypertension, whereas inhibition of HO ac-
tivity increases hypertension. The increase and decrease
in blood pressure as a result of the increase and decrease
in HO-1, respectively, is related to renal heme content.
Heme, a known prooxidant, has been shown to contribute
to the generation of reactive oxygen species (ROS) [39,
41, 42], and increased amounts of heme have been shown
to cause renal injury [43, 44]. In our study, the increase
in cellular heme may constitute a major factor in the
increased superoxide-mediated conversion of nitric ox-
ide (NO) to peroxynitrite and the increase in oxidative
stress indices observed as an increase in nitrotyrosine im-
munoreactivity. The increase in heme levels may also be
a reflection of the increased levels of heme proteins, in-
cluding COX-2, which was significantly increased in the
clipped kidneys from untreated 2K1C rats. Additionally,
COX activity was increased, as indicated by an increase
in urinary PGE2. These results are in agreement with
other reports suggesting that the COX pathway is ac-
tivated in 2K1C hypertensive rats as evidenced by an
increase in urinary excretion of both 6-keto-PGF1a and
TXB2 [45]. Other reports have shown that macula densa
COX-2 is up-regulated in high-renin states (i.e., as a con-
sequence of low sodium intake [32] or renal artery steno-
sis [46]) and following inhibition of RAAS [47]. COX-2
plays an important role in the regulation of renin re-
lease. Wang et al [34] have shown that COX-2 inhibition
decreases renin production and release in renovascular
hypertension. However, a report by Hartner et al [33]
demonstrated that COX-2 inhibition in established ren-
ovascular hypertension does not affect renin synthesis or
release, but only partially inhibits the increase in PRA
induced by a low salt diet.
Treatment of 2K1C rats with CoPP significantly in-
duced HO-1 expression and total HO activity and was
associated with a significant decrease in cellular heme,
oxidant levels, COX-2 expression in the clipped kidney,
and urinary PGE2 excretion. We have shown that CoPP
significantly increased HO-1 protein expression in the
cortex and outer medulla and, to a lesser degree, in the
inner medulla of the rat kidney and increased HO activ-
ity in both cortex and outer medulla [48]. HO-1 induction
by CoPP treatment greatly attenuated the development
of hypertension and improved the clipped/non-clipped
(L/R) kidney weight ratio (Table 1), suggesting amelio-
ration of renal hypertrophy. This effect was likely linked
to the HO-1–mediated decrease in heme content with
CoPP. In contrast, treatment with SnMP, which increased
heme content as a result of the decrease in HO activ-
ity, worsened renal atrophy in 2K1C rats. These results
suggest that one of the mechanisms by which HO-1 mod-
ulation affects kidney size in 2K1C is via control of the
cellular heme pool.
Another mechanism by which up-regulation of HO-1
decreases blood pressure may be related to an increase
in the level of CO and bilirubin, a potent antioxidant.
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Table 1. Effect of treatment with CoPP (5 mg/100 g body wt/week) or SnMP (three doses of 5 mg/100 g body wt/week) on left (L, clipped)/right
(R, non-clipped) kidney weight ratio in 2K1C rats
Sham 2K1C 2K1C+CoPP 2K1C+SnMP
L. kidney 1.277 ± 0.04 1.084 ± 0.06a 1.259 ± 0.05b 0.712 ± 0.17a,b
(clipped) g (N = 11) (N = 13) (N = 12) (N = 5)
R. kidney 1.296 ± 0.05 1.499 ± 0.05a 1.494 ± 0.05a 1.441 ± 0.04
(non-clipped) g (N = 11) (N = 13) (N = 12) (N = 5)
L/R kidney 0.989 ± 0.01 0.732 ± 0.04a 0.846 ± 0.02a,b 0.487 ± 0.12a,b
weight ratio (N = 11) (N = 13) (N = 12) (N = 5)
Results are expressed as mean ± SE.
aP < 0.05 vs. sham; bP < 0.05 vs. 2K1C.
These products may contribute to the renal cytoprotec-
tion in non-clipped kidney, where HO-1 is up-regulated
due to the increase in circulating Ang II and other inflam-
matory cytokines. Bilirubin can scavenge ROS [49–51]
and inhibit activation of NADPH oxidase [52] and pro-
tein kinase C (PKC) [53], which are key signaling steps in
oxidant-induced vascular injury. In humans, bilirubin lev-
els have been increasingly shown to be related to cardio-
vascular disease [54, 55]. Selective inhibition of biliverdin
reductase and the consequent reduction in bilirubin has
been shown to increase ROS by 3-fold [56]. Therefore,
increased HO-derived bilirubin may play a significant
role in decreasing oxidants in the 2K1C. In support of
this, recent studies have shown increased oxidative stress
in the Goldblatt 2K1C model [57], and that treatment
with the superoxide dismutase mimetic, tempol, normal-
ized the levels of oxidative stress and lowered blood pres-
sure [58]. Our study provides evidence that heme and
bilirubin might play an important regulatory role in ox-
idative stress. Targeting renal tissues with the human HO-
1 gene has also been recently shown to increase antioxi-
dant molecules, such as glutathione [59].
Since elevated plasma renin contributes to the devel-
opment of hypertension in the 2K1C model, we examined
the effect of CoPP on PRA. To our surprise, CoPP did not
decrease PRA in the 2K1C rats, but rather increased it.
Ploth et al [60] have shown that acute treatment of 2K1C
rats with verapamil, an antihypertensive calcium channel
blocker, significantly reduced blood pressure and also in-
creased PRA. In view of the fact that induction of HO-1
by CoPP results in the generation of CO, and that CO
has been shown to promote vasorelaxation through mul-
tiple mechanisms [61], the increased levels of PRA in the
CoPP-treated 2K1C rats may be in response to the va-
sorelaxation and decrease in blood pressure mediated by
the effects of CO.
Despite the increased PRA, plasma aldosterone levels
in the CoPP-treated 2K1C rats were significantly lower
than in untreated 2K1C rats. These results demonstrate
that induction of HO-1 by CoPP decreases aldosterone
synthesis. HO has been implicated as a major regula-
tor of CYP450 hemoproteins by limiting the amount of
heme and/or by producing CO, which strongly binds to
Fig. 8. Effect of treatment with CoPP (5 mg/100 g body wt/week) or
SnMP (three doses of 5 mg/100 g body wt/week) on left (L, clipped) and
right (R, non-clipped) kidney size. (A) Sham, (B) 2K1Cl control, (C)
2K1Cl treated with CoPP for three weeks, and (D) 2K1Cl pretreated
with SnMP for three weeks.
the heme moiety of CYP450 causing enzyme inhibition
[3]. Therefore, by limiting the availability of heme or by
increasing CO production, HO may inhibit the P450 en-
zymes required for aldosterone synthesis (P450scc and
P450 aldosterone synthase) and, consequently, reduction
in aldosterone synthesis may favor, at least in part, the
lowering of blood pressure observed in the CoPP-treated
2K1C rats. Another possible explanation is that induction
of HO-1 and the resulting decreased heme levels may in-
terfere with the action of Ang II in 2K1Cl rats, which
would explain the increase in PRA and decrease aldos-
terone levels. However, these new observations remain
to be investigated, including the possibility that HO-1 in-
duction may act as an AT1 receptor blocker. We have
previously shown that targeting the thick ascending limb
of the loop of Henle with human HO-1 gene decreases
Ang II-mediated DNA damage [62].
HO-1 has been shown to play a vital role in protecting
the kidney against various noxious stimuli. In the glycerol
model of acute renal failure, increased release of heme
proteins caused renal toxicity, whereas induction of HO-1
preserved renal function [63] and attenuated inflamma-
tory molecules [14]. Conners et al [64] demonstrated that
induction of HO-1 has an anti-inflammatory effect. This
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finding has been substantiated by studies from other lab-
oratories [65, 66]. Further, Wiesel et al have shown that
the absence of HO-1 and presumably an increase in heme
levels in the Goldblatt 1K1C model in mice leads to more
severe renovascular hypertension and an increase in is-
chemic damage [67]. In ischemia/reperfusion injury, heat
preconditioning or CoPP administration induced HO-1,
preserved kidney graft function, and prevented post-
perfusion apoptosis after cold preservation [68]. The salu-
tary effect of the enhancement of HO-1 activity has been
attributed by some to the HO-1–mediated increase in
GSH and extracellular superoxide dismutase levels, and
the decrease in iNOS [59, 62, 69]. The decrease in oxida-
tive stress has been shown to counteract vasoconstrictors,
including ET-1 and PE [18, 24, 25, 62, 69].
CONCLUSION
We conclude that administration of CoPP to 2K1C rats
significantly induced HO-1, which was associated with
decreased cellular heme levels and COX-2 expression in
the clipped kidney, increased PRA, and decreased plasma
aldosterone levels. This study also shows that HO-1 up-
regulation in the 2K1C rats prevents the development of
hypertension by decreasing cellular heme and increasing
CO and bilirubin synthesis, which induces vasodilation
(CO) and decreases oxidative stress (bilirubin). These
pharmacologic strategies to regulate the heme-HO sys-
tem may, in renovascular hypertension, have potential
clinical significance.
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